Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton’s tyrosine kinase (BTK ...
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reduc ...
Cross-continental collaboration brings US and Brazil expertise to create Southeast Asia's 1st propeller MRO licensed for ...
Sanofi’s LEAP2MONO phase 3 study of venglustat to treat type 3 Gaucher disease meets all primary endpoints: Paris Tuesday, February 3, 2026, 13:00 Hrs [IST] Positive results fro ...
Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher diseaseIn the LEAP2MONO phase 3 study, venglustat, dosed ...
Dr. David Nathanson is a professor of molecular and medical pharmacology at UCLA. He received his Ph.D. in molecular and medical pharmacology at UCLA under Dr. Paul Mischel, where he discovered that ...
Insilico Medicine has received investigational new drug clearance from the US Food and Drug Administration for ISM8969, an oral, brain-penetrant inhibitor of the NOD-like receptor family pyrin ...
This initiative explores how drones and ultra-low-volume spraying technologies can make crop adjuvant applications more sustainable, efficient, and profitable for farmers.
WD-40 has thousands of uses, many of which you can test out in the garage to help you clean the space, protect your equipment ...
Explore the role of the cPLA2 enzyme in brain inflammation related to Alzheimer’s disease and its potential as a therapeutic target.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results